REDDY-SITAGLIPTIN 100 MG
SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) : 100 MG · DIN 02536803 · DR REDDY'S LABORATORIES LTD
Health Canada status: APPROVED
What is REDDY-SITAGLIPTIN?
REDDY-SITAGLIPTIN 100 MG contains SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02536803, held by DR REDDY'S LABORATORIES LTD, supplied as TABLET for ORAL administration. Health Canada currently lists it as approved, status dated 31-Mar-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02536803 |
|---|---|
| Brand name | REDDY-SITAGLIPTIN |
| Generic / active ingredient | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) : 100 MG |
| Manufacturer | DR REDDY'S LABORATORIES LTD |
| Strength | 100 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A10BH01 SITAGLIPTIN |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 31-Mar-2023 |
What can be used instead?
Other Canadian products sharing ATC code A10BH01 SITAGLIPTIN. 53 of 77 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-SITAGLIPTIN | 100 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02512491 |
| ACH-SITAGLIPTIN | 25 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02512475 |
| ACH-SITAGLIPTIN | 50 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02512483 |
| AG-SITAGLIPTIN | 100 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02535548 |
| AG-SITAGLIPTIN | 25 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02535513 |
| AG-SITAGLIPTIN | 50 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02535521 |
| APO-SITAGLIPTIN | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02428296 |
| APO-SITAGLIPTIN | 25 MG | TABLET | APOTEX INC | MARKETED | DIN 02428261 |
| APO-SITAGLIPTIN | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02428288 |
| APO-SITAGLIPTIN MALATE | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02508672 |
Who else supplies SITAGLIPTIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SITAGLIPTIN appears in 725 registered pack listings across 12 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.